Hasil Pencarian (1)
small molecule | CAS: 1642288-47-8
Mavacamten is a myosin inhibitor indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM). It received initial US FDA approval in 2022, and it is one of the first myosi…
Kategori:
AminesBenzene DerivativesBenzyl Compounds
+21
Target Protein:
Myosin-7
Waktu ParuhMavacamten has a va…
Vol. DistribusiThrough the use of …
KlirensMavacamten demonstr…
Genetik
-